BAY 1817080

Drug Profile

BAY 1817080

Latest Information Update: 21 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cough

Most Recent Events

  • 21 Oct 2017 Bayer plans a phase I trial for Cough in October 2017 (NCT03310645)
  • 01 Jul 2016 Bayer plans a phase I trial of BAY 1817080 in Healthy volunteers in Germany (NCT02817100)
  • 30 Jun 2016 Preclinical trials in Undefined indication in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top